NCT04847557 trial results

Inclusion Criteria: * Have a diagnosis of stable heart failure (NYHA class II-IV) and left ventricular ejection fraction (LVEF) ≥50% * Elevated NT-proBNP (N-terminal pro B-type natriuretic peptide) \> 200 picogram/milliliter (pg/ml) for participants without atrial fibrillation (AF), or \>600 pg/ml for participants with AF, Structural heart disease (Left atrial enlargement) or Elevated left ventricular filling pressure * Estimated glomerular filtration rate (eGFR) \<70 milliliter (ml)/minute (min)/1.73m² at screening, or HF decompensation within 12 months of screening, * Stable dose of heart failure medications within 4 weeks of screening * Body mass index (BMI) ≥30 kilograms per meter squared (kg/m²) * 6MWD 100-425 meters * KCCQ CSS ≤80 Exclusion Criteria: * Have had a major cardiovascular event within the last 90 days of screening * Have had acute decompensated heart failure within 4 weeks of screening * Have non cardiac causes of functional impairment such as pulmonary arterial hypertension (PAH), severe chronic obstructive pulmonary disease (COPD), anemia, thyroid disease, musculoskeletal disease or orthopedic conditions * Presence of cardiac amyloidosis, cardiac accumulation disease, cardiomyopathy and severe valvular heart disease * HbA1c ≥9.5% or uncontrolled diabetes * History of proliferative diabetic retinopathy or diabetic maculopathy * Have a history of pancreatitis * eGFR \<15 mL/min/1.73 m² or requiring dialysis at screening